Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Stock Price Up 1.1% – Here’s What Happened

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP)’s share price was up 1.1% on Monday. The company traded as high as $3.85 and last traded at $3.78. 85,688 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 367,441 shares. The stock had previously closed at $3.74.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Armata Pharmaceuticals in a report on Tuesday, September 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Armata Pharmaceuticals Stock Up 1.1%

The stock has a market cap of $140.54 million, a PE ratio of -0.50 and a beta of 1.34. The business’s fifty day moving average is $4.84 and its 200 day moving average is $7.21.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last issued its earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.17. Armata Pharmaceuticals had a negative net margin of 3,467.04% and a negative return on equity of 12.24%. The company had revenue of $2.51 million for the quarter, compared to analyst estimates of $0.40 million. As a group, analysts predict that Armata Pharmaceuticals, Inc. will post 0.5 EPS for the current year.

Institutional Investors Weigh In On Armata Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Madison Asset Management LLC purchased a new position in Armata Pharmaceuticals in the 1st quarter valued at approximately $21,583,000. BlackRock Inc. purchased a new stake in Armata Pharmaceuticals during the second quarter worth $3,629,000. 683 Capital Management LLC acquired a new stake in Armata Pharmaceuticals in the fourth quarter valued at $878,000. Sei Investments Co. acquired a new stake in Armata Pharmaceuticals in the first quarter valued at $760,000. Finally, Bank of New York Mellon Corp acquired a new stake in Armata Pharmaceuticals in the second quarter valued at $193,000. Institutional investors and hedge funds own 3.57% of the company’s stock.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapies for serious bacterial infections. Bacteriophages, or phages, are viruses that selectively infect and destroy specific bacteria. Armata’s approach is intended to address drug-resistant infections while limiting disruption to beneficial bacteria.

The company’s pipeline has included inhaled phage products designed to treat chronic respiratory infections caused by Pseudomonas aeruginosa, including infections associated with cystic fibrosis and other structural lung diseases.